Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Entrada Therapeutics to post earnings of ($1.06) per share and revenue of $2.9190 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. The business had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. On average, analysts expect Entrada Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock traded down $0.04 during midday trading on Tuesday, reaching $15.75. 401,985 shares of the company’s stock traded hands, compared to its average volume of 217,130. The company has a market cap of $611.42 million, a price-to-earnings ratio of -4.55 and a beta of -0.09. Entrada Therapeutics has a 52 week low of $4.93 and a 52 week high of $16.19. The company’s 50 day simple moving average is $12.72 and its 200 day simple moving average is $10.75.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Wall Street Zen downgraded shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Cantor Fitzgerald assumed coverage on shares of Entrada Therapeutics in a report on Wednesday, April 1st. They issued an “overweight” rating on the stock. Finally, Oppenheimer lifted their target price on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Entrada Therapeutics has an average rating of “Moderate Buy” and an average price target of $19.00.

Insider Transactions at Entrada Therapeutics

In other news, insider Natarajan Sethuraman sold 25,907 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.39, for a total transaction of $398,708.73. Following the transaction, the insider owned 216,317 shares in the company, valued at approximately $3,329,118.63. The trade was a 10.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kory James Wentworth sold 11,388 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $13.02, for a total transaction of $148,271.76. Following the transaction, the chief financial officer owned 121,510 shares in the company, valued at approximately $1,582,060.20. The trade was a 8.57% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 82,882 shares of company stock worth $1,169,103. 9.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TRDA. State of Wyoming increased its holdings in shares of Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after purchasing an additional 4,295 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares during the period. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics in the second quarter valued at about $68,000. Jain Global LLC bought a new stake in Entrada Therapeutics in the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC bought a new stake in Entrada Therapeutics in the second quarter valued at about $72,000. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.